Qube Research & Technologies (QRT)
SABS icon

Qube Research & Technologies (QRT)’s SAB Biotherapeutics SABS Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,098
Closed -$92.3K – 3984
2026
Q1 		$92.3K Sell
24,098
-7,049
-23% -$28.1K ﹤0.01% 3076
2025
Q4 		$116K Buy
+31,147
New +$102K ﹤0.01% 3168
2024
Q3 		– Sell
-6
Closed -$19 – 3995
2024
Q2 		$19 Hold
6
– – ﹤0.01% 3582
2024
Q1 		$27 Sell
6
-1
-14% -$6 ﹤0.01% 4253
2023
Q4 		$47 Hold
7
– – ﹤0.01% 4074
2023
Q3 		$43 Buy
+7
New +$51 ﹤0.01% 3828
2022
Q2 		– Sell
-2,418
Closed -$91K – 3051
2022
Q1 		$91K Buy
2,418
+736
+44% +$34K ﹤0.01% 2089
2021
Q4 		$131K Buy
+1,682
New +$158K ﹤0.01% 2079

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Qube Research & Technologies (QRT)'s SABS Position: Q2 2026 in Review

Qube Research & Technologies (QRT) sold out of SAB Biotherapeutics (SABS) in Q2 2026, closing a stake of 24,098 shares — an estimated $92.3K sold.

Qube Research & Technologies (QRT) first reported a position in SABS in Q4 2021 and held it in 8 quarters. The position peaked at $131K in Q4 2021. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Qube Research & Technologies (QRT) reported no remaining SAB Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 24,098 SAB Biotherapeutics shares in Q2 2026, an estimated $92.3K.
  • Qube Research & Technologies (QRT) first reported a position in SAB Biotherapeutics in Q4 2021 and held it in 8 quarters.
  • Qube Research & Technologies (QRT)'s SAB Biotherapeutics position peaked at $131K in Q4 2021.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.